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Acinetobacter baumannii is a third most common, Gram-negative, opportunistic 
pathogen responsible for nosocomial (hospital-acquired) infections in healthcare units 
world-wide. Carbapenems are  considered to be the last resort to treat such infections but  
a recent increased in resistance of A. baumannii against carbapenem group of 
antimicrobial agents is posing great threat in control of this pathogen  and leading to 
almost no therapeutic options available for clinicians to treat such infections. Joshi 
Laboratory recently isolated multidrug-resistant, carbapenem-resistant A. baumannii 
(CRAB) bacterial pathogens from Drexel University College of Medicine’s Hahnemann 
University Hospital, which exhibits multiple mechanisms of carbapenem resistance. The 
membrane-associated drug-efflux pump is one of the major mechanisms of carbapenem 
resistance, which works by effluxing carbapenem and other classes of antibiotics in A. 
baumannii. The current pump inhibitors used in clinical set up are non-effective due to 
the increased resistance against them or confer high toxicity. Joshi Laboratory reported 
novel antimicrobial non-thermal plasma-activated antibacterial solutions which are 
broad-spectrum in nature. These antibacterial solutions are being explored for their exact 
mechanisms of action on prototype pathogen, clinical isolate #22 which is CRAB.  The   
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specific aim of present study is to re-confirm the findings of antimicrobial effect of non-
thermal plasma-activated novel antibacterial solution, and determine the effect of 
commonly used efflux-pump inhibitor, carbonyl cyanide m-chlorophenyl hydrazone 
(CCCP) and non-thermal plasma-activated antibacterial solution on locally isolated 
CRAB # 22, and correlate with inhibition of drug-efflux pump. This research work is 
complementary to past and current research being carried out in Joshi Laboratory at 
Drexel University (1, 2). In the present study, we re-confirmed that non-thermal plasma 
activated methionine solution at 3 minutes of plasma treatment and 15 minutes of holding 
time results in complete inactivation of Acinetobacter baumannii. We found that pump 
inhibitor CCCP didn’t decrease the MIC of amikacin and tetracycline susceptibility of 
CRAB isolate #22 and also didn’t have significant effect on the susceptibility of 
meropenem. As many of the efflux pumps share the same structural homology, therefore 
there might be other efflux pumps that are able to affect the susceptibility of given strain. 
Till now no current pump inhibitors are licensed to use in clinical set ups because of the 
difference between concentrations being used in clinical set up and effective 
concentration of pump inhibitor. Therefore this area needs further research so that new 
efflux pump inhibitors can be developed to control the mortality rate of infections 
associated with MDR pathogens. In order to investigate the effect of plasma-treated 
antibacterial solution on inhibition of drug-efflux pumps, other efflux pump inhibitors 
may be tested for the given isolate that may have significant effects in inhibition of efflux 
pump.  
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                                                        CHAPTER 1: INTRODUCTION 
 
1.1 Background 
 Acinetobacter baumannii is the third most important opportunistic pathogen responsible 
for hospital-acquired infections and poses a great threat to healthcare facilities in the 
modern era of antibiotics worldwide. A. baumannii is a non-fastidious, non-motile, gram-
negative coccobacillus responsible for urinary tract infections, wound and soft tissue 
infections, blood stream infections, and ventilator-associated pneumonia. It is also 
associated with infections outside of the healthcare setting, such as community-acquired 
pneumonia and skin infection. Carbapenems are considered to be the last resort to treat 
such infections, but due to a recent rise in resistance towards the carbapenem group of 
antimicrobials, it has become a challenge to control this pathogen. There are various 
mechanisms by which this organism acquires resistance, such as inactivation of enzymes, 
modification of target sites, decreased influx, increased efflux, and the presence of active 
or functional efflux pumps. The presence of active efflux pumps is one of the prominent 
mechanisms of acquiring resistance by this organism. 
Efflux pumps are located in the cytoplasmic membrane of bacteria and are responsible 
for extruding toxic substances. Active efflux pumps require energy to perform their 
activity. Overexpression of these pumps is responsible for the increased resistance 
towards antibiotics. This overexpression can be due to mutation in the operon that is 
regulating these pumps. There are pump inhibitors available, but due to increased 
resistance to them, current pump inhibitors have become non-effective in the clinical   
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context. Thus, in order to understand the resistance mechanism of this organism, it is 
necessary to elaborate the importance of these pumps and available pump inhibitors. 
One commonly used efflux-pump inhibitor is carbonyl cyanide m-chlorophenyl 
hydrazone (CCCP). CCCP is known to disrupt the proton gradient of the cytoplasmic 
membrane of the organism, which results in the increase of the susceptibility of the 
organism towards antimicrobial agents. It is a widely used pump inhibitor for phenotypic 
pump inhibition assays (3). 
Recently, non-thermal plasma-based technologies have emerged in the control of 
microbial contaminants. It has been demonstrated that non-thermal plasma-activated 
solutions are broad-spectrum antimicrobial in nature and contain reactive species, having 
the capability of inducing severe oxidative stress, which can lead to lipid peroxidation of 
the bacterial membrane, oxidation of cellular proteins, and DNA damage leading to cell 
death. Although these antimicrobial solutions are able to inactivate resistant pathogens, 
we do not know the exact mechanism of action yet.  
Therefore, in the present study, we will first confirm the previous findings of the 
antimicrobial effect of a non-thermal plasma-activated novel antibacterial solution, 
determine the effect of the commonly used efflux-pump inhibitor CCCP and non-thermal 
plasma-activated antibacterial solution on locally isolated carbapenem-resistant A. 
baumannii (CRAB) #22, and correlate these effects with inhibition of the drug-efflux 
pump.The Joshi Laboratory reported novel antimicrobial non-thermal plasma-activated 
antibacterial solutions including N-acetyl cysteine (NAC) and methionine, which are 
broad-spectrum in nature. This research work is complementary to past and current 
research being carried out in the Joshi Laboratory at Drexel University (1, 2).  
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1.2 Aims  
1. To reconfirm the previous findings of the antimicrobial effect of a non-thermal 
plasma-activated novel antibacterial solution, methionine  
2. To determine the effect of a commonly used efflux-pump inhibitor, CCCP, on 
locally isolated CRAB #22 
3. To determine the effect of a non-thermal plasma-activated antibacterial solution, 
methionine, on locally isolated CRAB #22 and correlate this effect with inhibition 
of the drug-efflux pump 
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CHAPTER 2: REVIEW OF LITERATURE 
 
2.1 Acinetobacter baumannii   
The genus Acinetobacter includes gram-negative, nonmotile, aerobic coccobacilli. 
Acinetobacter baumannii, the most important species of this genus, has turned out to be 
the most important in healthcare facilities due to its resistance towards most antibiotics  
(4).  A. baumannii is known to be an opportunistic pathogen causing nosocomial 
infections, e.g., ventilator-associated pneumonia, urinary tract infections, secondary 
meningitis, bloodstream infections, wound and soft tissue infections, and community-
based infections such as community-acquired pneumonia and skin infection. Hospital-
acquired pneumonia caused by A. baumannii has a great prevalence of bacteremia and a 
40-64% mortality rate (5).  Increasing resistance towards various clinically available 
drugs and antibiotics has placed A. baumannii among the top seven pathogens causing 
alarm in the clinical setting and healthcare institutions (6). A. baumannii is a member of 
ESKAPE (extended-spectrum β-lactamase (ESBL)-positive Escherichia coli, methicillin-
resistant Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, 
Pseudomonas aeruginosa, and carbapenem-resistant Enterococcus faecalis) group of 
pathogens, a priority area identified by the Center for Disease Control and Prevention and 
National Institutes of Health.   
A. baumannii is resistant to commonly used antibiotics comprising first-, second-, and 
some third-generation cephalosporins, chloramphenicol, broad-spectrum β-lactams, 
tetracyclines, aminoglycosides, and some polymyxins (5). Due to its ability to survive in   
5 
 
 
 
the hospital environment for a longer period of time and strong biofilm producing 
capabilities, multidrug-resistant (MDR) isolates are of major concern for contamination 
and a great challenge for healthcare facilities. Carbapenems have been the last 
antimicrobial therapeutic option to treat A. baumannii infections, but a recent surge in 
carbapenem resistance in A. baumannii has been widely reported worldwide (7).   
2.2 Mechanisms of resistance in Acinetobacter baumannii 
There are various mechanisms by which bacteria survive against antibiotics, e.g., 
inactivation of enzymes, modification of the target sites, alterations in the membrane 
porin system, and involvement of active efflux pumps (5). Aminoglycoside resistance via 
modification of enzymes is prevalent in the isolates of A. baumannii causing nosocomial 
infections (8). Species of Acinetobacter acquire β-lactamases that provide resistance to 
cephalosporins, carbapenems, and penicillins (7).  
Two strains of Acinetobacter, AYE and SDF, provide much information about the 
resistance genes in this organism. The human isolate AYE is MDR and the SDF isolate, 
which is isolated from body lice, is susceptible to antibiotics (9). There is an 86-kb 
resistance island named AbaR1 identified in the AYE isolate found by Fournier et al. 
(10). This island has 45 resistance genes and among them the most important ones are 
known to be coding for AmpC, VEB-1, OXA-10 β-lactamases, AMEs, and tetracycline 
efflux pumps (10).  
It has been found that transposons play an important role in dissemination of resistance 
determinants and many of them possess integrons, mostly class 1 integrons (10). 
Integrons are the genetic structures that possess an integrase gene (intI), recombination   
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site (attI), and one or two promoters. Six classes of integrons have been characterized to 
date and among them class 1 are found to be largely involved in dissemination of 
antibiotic resistance in clinical isolates (11).  Integron-borne β-lactamases along with 
non-β-lactam resistance genes are found to threaten the potential  of antibiotics by giving 
rise to MDR phenotypes (12). Insertion sequences also play an important role in 
elucidating the resistance genes and their expression. The novel insertion sequence IS 
(Aba-1) has been found in A. baumannii (13), which results in increased expression of 
AmpC (10). ISAba-1 sequences have been found in ceftazidime-resistant strains of A. 
baumannii (14).   
Biofilm formation is another important feature through which bacteria can survive the 
surveillance of the immune system of the host (15). Thus, biofilm is known to be the 
survival strategy for many pathogenic organisms, including A. baumannii. In planktonic 
form during unfavorable conditions or upon exposure to specific stimulation, biofilm can 
be formed. In biofilm, bacteria slow down their rate of metabolism and protect 
themselves from external factors such as biocides and antibiotics by embedding within 
their own secreted extracellular polysaccharide biomatrix.  A biofilm upon maturity 
periodically releases cells, giving rise to more, discrete, satellite colonies of bacteria that 
in turn form new biofilms and help in spreading infection. It has been found that 
infections associated with biofilms result in very high mortality rates. Therefore, a 
strategy of controlling biofilm also helps in controlling the spread of infections (2).  
2.2.1 Carbapenem resistance in Acinetobacter baumannii 
 The β-lactams are commonly used antimicrobial agents in children, but increased 
resistance against β-lactams has become an important concern in pediatric treatment   
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strategies. Bacteria acquire resistance against β-lactams via enzymes that hydrolyze β-
lactams called β-lactamases.  
Resistance to β-lactams is generally caused by metallo-β-lactamases, oxacillinases, and 
ESBLs (16).  Many ESBLs have been reported in A. baumannii, including VEB-1, PER-
1, TEM-92, TEM-166, SHV-12, CTX-M-2, and CTX-M-43, in addition to narrow-
spectrum β-lactamases such as TEM-1 and TEM-2. The latter ones have limited clinical 
significance (4).  
Carbapenemases are enzymes that can inactivate almost all β-lactam antimicrobial agents 
(17). The increasing incident of carbapenem resistance in A. baumannii poses a major 
threat to the antibiotic era.  CRAB isolates have various mechanisms for acquiring 
resistance against carbapenems. The prime factor is class D carbapenemases (18).   
There are two types of carbapenemases based upon their mechanism of hydrolysis. The 
first type is metalloenzymes, also known as metallo-β-lactamases (MBLs). These contain 
a zinc ion at their active site, which is responsible for hydrolysis of the β-lactam ring. 
Ethylenediamine tetraacetic acid (EDTA), which is known to be a chelating agent, is 
capable of chelating the zinc ion of MBLs and therefore inhibiting enzyme activity. But 
later, other carbapenemases were reported in which EDTA was unable to inhibit activity.  
The second type is serine β-lactamases, which possess serine at the active site for 
hydrolysis (17, 19).   
Three of the MBLs, namely IMP, VIM, and SIM, are commonly found in A. baumannii, 
of which the IMP and VIM variants render remarkable resistance to carbapenem. The 
second most important β-lactamases present in this organism are oxacillinases,   
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characterized by oxa-51 and oxa-69 variants, but among them oxa-69 is known to have a 
minor effect on β-lactam susceptibility along with carbapenems.  Oxacillinases that can 
hydrolyze imipenem are grouped under carbapenem-hydrolyzing oxacillinases (CHDLs), 
which are specific to A. baumannii. CHDLs are known to be susceptible to inhibition by 
NaCl (20). 
Thus, β-lactamase production in bacteria determines their resistance to the β-lactam 
antimicrobial agent.  
Recently, it has also been found that outer membrane proteins (OMPs) play an important 
role in carbapenem resistance. According to Limansky et al. (20), imipinem resistance in 
clinical isolates of A. baumannii is correlated with loss of a 29-kDa OMP, interestingly in 
which there was no carbapenemase activity. In MDR isolates of A. baumannii, resistance 
to imipenem and meropenem is known to be correlated with the loss of a 29-kDa OMP 
named carO. Thus, reduced permeability could also lead to carbapenem resistance (20). It 
has been found that there are three types of porin families that confer resistance to 
carbapenems, namely substrate specific, nonspecific, and efflux porins. Carbapenem 
resistance due to overexpression of efflux porins has been found in A. baumannii (21).  
2.2.2 Active efflux pumps 
Another important mechanism of resistance includes the involvement of active efflux 
pumps, which prohibit the antibiotic from entering the bacterial cell and efflux the 
antibiotic. These pumps can transport different classes of antibiotics, leading to MDR 
phenotypes and are therefore of clinical significance. Five families of efflux pump 
proteins have been found to be associated with MDR status (22): the ABC (ATP binding 
cassette) superfamily, the MFS (major facilitator) superfamily, and the MATE (multidrug  
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 and toxic compound extrusion) and RND (resistance nodulation division) families.  The 
ABC superfamily belongs to the family of trans-membrane proteins that bind to ATP, use 
ATP hydrolysis as an energy source, and transport a range of molecules (23). The MFS 
superfamily includes CraA, which is correlated with chloramphenicol resistance in A. 
baumannii (24). The MATE and RND families include AdeIJK, which is found in the 
clinical isolate BM5554 of A. baumannii and is resistant to many antibiotics such as β-
lactams, chloramphenicol, tetracycline, novobiocin, and rifampin (25). A single organism 
can have more than one type of family as well (22).  
It has been found that the most prevalent drug-efflux system in A. baumannii belongs to 
the RND family, of which the most important systems explained in details are AdeABC, 
AdeIJK, and AdeFGH (26). The RND efflux complex is made up of two important 
constituents that help in transport of drugs across the outer membrane. One is 
cytoplasmic membrane transporter protein, which interacts with an OMP, and the second 
one is periplasmic membrane fusion protein (MFP) (27). AdeABC codes for AdeA MFP, 
multidrug transporter AdeB, and AdeC OMP. Overexpression of this pump is responsible 
for MDR in A. baumannii (28). A 2- to 8-fold reduction in resistance has been found after 
addition of efflux pump inhibitors, such as CCCP and 1-(1-(naphthylmethyl)piperazine, 
which shows the involvement of efflux pumps. A decrease in the minimum inhibitory 
concentration (MIC) of imipenem has been found in the presence of CCCP.  Thus, 
overexpression of AdeABC results in resistance to carbapenems, but efflux is not 
necessarily the only mechanism responsible for increasing the resistance; it can weakly 
increase the MICs. Thus, the involvement of other resistance mechanisms along with 
efflux can confer high levels of resistance in bacteria. It has been found that mutations in   
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AdeRS regulate the expression of AdeABC, which means AdeRS functions as a 
transcriptional activator. But mutants that overexpress AdeABC have been found in 
which there is no mutation in AdeRS, which means there are chances of other 
mechanisms involved.  AdeIJK had been found to be in synergy with AdeABC. It has 
been found that inactivation of AdeIJK or of overexpressed AdeABC results in a 3- to 8-
fold decrease in the MIC of tigecycline whereas inactivation of both pumps results in an 
85-fold decrease in MIC. A third type of RND is AdeFGH, encoded by the operon 
adeFGH. Its overexpression confers MDR (28). Figure 1 show the representation of these 
operons where arrows indicate the direction of transcription. 
 
Figure 1. Operon representation of RND efflux system in A. baumannii (28) 
 
In A. baumannii, nine efflux systems that are included under secondary multidrug 
transporters have been found. AdeABC, AdeIJK, and AdeFGH included in the RND 
family (described previously) provide resistance to a wide spectrum of antibiotics. AbeM, 
belonging to the MATE family, confers mild resistance to many of the antimicrobial 
agents. Tet(A), Tet(B), CraA, and AmvA, belonging to the MFS family, provide 
resistance to tetracycline, minocycline, chloramphenicol, and erythromycin, respectively. 
AbeS belongs to the SMR (small multidrug resistance) family (29). According to one 
article, the cloned abeS gene in the hypersensitive E. coli host KAM32 is responsible for   
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decreased susceptibility to many antimicrobial agents, detergents, and dyes and its 
deletion in A. baumannii confirms its role of providing resistance to these compounds 
(30). 
2.3 Non-thermal plasma-treated solution as an antimicrobial agent 
In physics, plasma is defined as an ionized medium, usually gas, which produces 
electrons, ions, uncharged atoms, and electronically excited atoms, radicals, and UV 
photons. Lasers and thermal plasma have been used in the field of medicine to cauterize 
tissues through heating, such as the argon plasma coagulator. In thermal plasma, the 
temperature of gas can go far beyond room temperature and therefore the process is 
nonselective and difficult to control, but in non-thermal plasma, there is no heat. Thus, 
the process can be easily controlled.  
There are various methods to produce non-thermal plasma, but the one created by 
dielectric barrier discharge (DBD) has dose-dependent effects. In DBD, high voltage is 
applied between two electrodes. One of the two electrodes is insulated in order to prevent 
building of current so that safe plasma can be created without heating of the gas. Most of 
the literature has paid attention to the bactericidal effects of plasma (31). Recently, non-
thermal plasma is of high significance due to its antimicrobial effect.  It has been reported 
that under plasma treatment, UV radiation, formation of reactive species, and electric 
fields are the major factors responsible for microbial inactivation. Plasma discharges 
reactive nitrogen and oxygen species that play significant roles. It has been demonstrated 
that this technology inactivates the pathogens in planktonic forms as well as in biofilm 
forms (1). The most important species created are superoxide, singlet oxygen, OH 
radicals, hydrogen peroxide, and ozone.  It has been reported that plasma-treated liquids  
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 are bactericidal against many pathogenic organisms (32). All of these species are able to 
cause oxidative damage to bacterial organisms. Oxidative stress leads to lipid 
peroxidation and extensive damage leads to cell death. Reactive oxygen species are 
known to be the key regulator in lipid peroxidation (33).  
Previously, it has been reported that plasma-activated chemical solutions can inhibit 
biofilm formation by MDR isolates; for example, plasma-activated methionine solution 
can inhibit biofilm formation by carbapenem-resistant A. baumannii, methicillin-resistant 
Staphylococcus aureus, Enterococcus faecalis, and metallo-β-lactamase-positive 
Klebsiella pneumonia (2).  
2.3.1 Factors involved in the antimicrobial effect of non-thermal plasma: According 
to Ikawa et al. (1), a pH of 4.7 is known to be the critical value for the inactivation of 
microorganisms. They reported that when the pH is below 4.7, antimicrobial activity of 
plasma-activated liquid is effectively greater than a liquid with a pH higher than 4.7. 
Thus, acidic pH is essential for the antimicrobial activity of plasma-activated solutions; 
however, it is not the only source of antimicrobial effect. In plasma-treated liquids, many 
species such as nitrate, nitrite, hydrogen peroxide, and other reactive nitrogen and oxygen 
species such as super oxide and nitric oxide have been found. These species react to form 
another species, which may contribute to antimicrobial activity (1). These reactive 
species can easily diffuse through the cell membrane and attack biomolecules that 
ultimately leads to lipid and protein nitrosylation and intracellular oxidation, which 
ultimately contributes to cell death (1).   
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For example, plasma-treated NAC solution has been found to exhibit antimicrobial 
property. It has been found that plasma-treated NAC solution forms acetic acid and 
cysteic acid (1) as shown below: 
𝐶5𝐻9𝑁𝑂3𝑆 + 𝐻𝑂𝑂
−   ⟶  𝐶3𝐻7𝑁𝑂5𝑆    +        𝐶2𝐻4𝑂2                                          
Equation (1) 
    (NAC)                             (Cysteic acid)         (Acetic acid)   
Acetic acid and cysteic acid are responsible for a drop in pH after the plasma treatment 
and subsequently antimicrobial activity. A pH of ~2.3-2.5 of the species exhibits an 
antimicrobial effect (1).  
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                                                  CHAPTER 3: METHODS  
 
3.1 Setting of Dielectric Barrier Discharge 
Non-thermal plasma treatment of methionine solution was carried out essentially as 
described earlier by our laboratory.  
 
 
                                                                        
 
                           
 
    Figure 2. Setup of non-thermal dielectric barrier discharge (2) 
  
The DBD technique was used to create non-thermal plasma (Figure 2). In this technique, 
high voltage is supplied between two electrodes separated by an insulating dielectric 
barrier. Dielectric cannot pass a dc current because of being an insulator. The amount of 
displacement current that can cross through the dielectric is determined by the dielectric 
constant and the thickness of the dielectric along with the time derivative of applied 
voltage. In order to transport the current, the electric field should be high enough to cause   
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breakdown of the gas, resulting in microdischarges. The gas acts as a reservoir and 
energy dissipated by the microdischarges is absorbed by it and then it transports the long-
lived species (34). DBDs generally work at sinusoidal voltages of frequencies between 
0.05 and 500 kHz or high voltage pulses (35). 
In our study, the parameters used for treatment were set at a voltage of 31.4 kV, an 
intensity of 0.29 W/cm^2, a pulse frequency of 1.5 kHz, and a pulse duration of 10 
microseconds (2). A customized glass slide, which can hold 500 µL of liquid, was used to 
hold the liquid being treated during plasma treatment. A gap of 2 mm was set between 
the surface of electrode and the liquid being treated (2).  
3.2 Solution and non-thermal plasma treatment 
100 mM stock solution was prepared in phosphate-buffered saline (PBS), sterilized 
through filter membranes, and stored in aliquots at -20°C. A 5 mM working solution of 
methionine was freshly prepared by diluting the stock solution in PBS and used for 
plasma treatments.  
3.3 Bacterial strains 
Acinetobacter baumannii ATCC 19606 and MDR CRAB #22 from our laboratory were 
used. Cultures were prepared in trypticase soy broth (TSB) and incubated at 37°C 
overnight.  
3.4 Procedure for non-thermal plasma treatment  
Day 1:   
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1. A. baumannii 19606 was inoculated from a plate into 15-20 mL TSB and 
incubated overnight at 37°C. 
Day 2:  
1. The optical density (OD) of overnight bacterial cultures was determined using a 
spectrophotometer at 600 nm and was set as 0.2 (1x108 colony-forming units 
[CFU]/mL) 
2. A 1:1000 dilution of bacterial culture (0.2 OD600) with PBS was prepared for 
colony count assay. 
Calculation: 10 ml of 1:1000 dilutions 
 
(𝐹𝑖𝑛𝑎𝑙 𝑉𝑜𝑙𝑢𝑚𝑒)
(𝑆𝑜𝑙𝑢𝑡𝑒 𝑉𝑜𝑙𝑢𝑚𝑒 )
= 𝐷𝑖𝑙𝑢𝑡𝑖𝑜𝑛 𝐹𝑎𝑐𝑡𝑜𝑟  
 
10,000/Solute Volume = 1000 
Solute Volume = 10 µL 
Take 10 µL of bacterial solution and dilute it to 10,000 µL - 10 µL = 9990 µL of 
diluent (PBS) 
3. A working solution of 5 mM concentration of methionine solution in PBS was 
prepared from a 100 mM stock solution. 
4. Plasma treatment was carried out for 1, 2, and 3 minutes for methionine solution. 
5. Plasma-treated solutions were then exposed to diluted bacterial culture for 15 
minutes at a 1:1 ratio (100 µL of bacterial culture was exposed to 100 µL of 
plasma-treated or untreated solution).  
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6. A colony count assay was performed according to the serial dilution technique.  
1:100 serial dilutions were made and 100 µL of diluted solution from each sample 
was plated on nutrient agar plates. 
 
𝐷𝑖𝑙𝑢𝑡𝑖𝑜𝑛 =
(𝑉𝑜𝑙𝑢𝑚𝑒 𝑇𝑟𝑎𝑛𝑠𝑓𝑒𝑟𝑟𝑒𝑑 )
𝑉𝑜𝑙𝑢𝑚𝑒 𝑇𝑟𝑎𝑛𝑠𝑓𝑒𝑟𝑟𝑒𝑑 + 𝐷𝑖𝑙𝑢𝑒𝑛𝑡 𝑉𝑜𝑙𝑢𝑚𝑒
 
 
7. Plates were incubated at 37°C for 18-24 hrs.  
Day 3: 
      1. CFU were counted on every plate and results were interpreted for antimicrobial    
activity of plasma-treated solutions. 
 
𝐶𝐹𝑈
𝑚𝐿
=
(𝐶𝑜𝑙𝑜𝑛𝑖𝑒𝑠 𝐹𝑜𝑟𝑚𝑒𝑑 )
𝐷𝑖𝑙𝑢𝑡𝑖𝑜𝑛 ∗ 𝑉𝑜𝑙𝑢𝑚𝑒 (𝑚𝐿) 𝑃𝑙𝑎𝑡𝑒𝑑 
 
 
After successful interpretation of results, the next step was to see the effect of plasma-
treated solutions on the drug-efflux pumps of A. baumannii. 
3.5 Antibiotic susceptibility testing 
Antibiotic susceptibility testing was carried out to determine the MICs of three 
antibiotics, namely meropenem, tetracycline, and amikacin.  
This testing was carried out by the broth microdilution method according to Clinical and 
Laboratory Standard Institute (CLSI) guidelines (36).   
3.5.1 Minimum inhibitory concentration assay procedure by broth microdilution 
method:    
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Day 1:  
1. Cultures of A. baumannii ATCC 19606 and CRAB #22 were prepared in Mueller-
Hinton broth (MHB) and incubated at 37°C overnight. 
Day 2:  
1. The OD of overnight bacterial cultures was determined using a spectrophotometer 
at 600 nm and was set as 0.2 (1x108 CFU/mL).  
2. A 2x highest tested concentration of antibiotic was prepared and diluted 1:2 while 
adding to a 96-well microtiter plate.  
3. 90 µL of MHB was added to each well being tested (96 wells). 
4. 90 µL of antibiotic was added and serially diluted to the lowest concentration.  
5. Culture was diluted and added to each well being tested in such a way that its 
concentration per well was 5x105 CFU/mL as recommended by the CLSI. 
6. The positive control well had MHB and organisms and the negative control 
(blank) had antibiotic but no organisms.  
7. The microtiter plate was closed and incubated at 37°C for 18-24 hrs.  
Day 3: 
      1. The microtiter plate was read for absorbance in a spectrophotometer at 600 nm and 
the MIC was calculated as described.  
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3.5.2 Pump inhibition assay 
 In order to analyze the effects of efflux pumps in antimicrobial resistance, we 
determined the MIC of antibiotics with or without the efflux pump inhibitor CCCP. A 
concentration of 12.5 µM of CCCP was used for all three antibiotics (meropenem, 
amikacin, and tetracycline).  
Day 1:  
1. Cultures of A. baumannii ATCC 19606 and CRAB #22 were prepared in MHB 
and incubated at 37°C overnight. 
Day 2:  
1. The OD of overnight bacterial culture was determined using a spectrophotometer 
at 600 nm and was set as 0.2 (1x108 CFU/mL).  
2. The 0.2 OD600 culture was diluted 10 fold in saline (100 µL of 0.2 OD600 culture 
diluted in 900 µL of PBS). 
3. Mueller-Hinton agar (MHA) was prepared and after autoclaving it was allowed to 
cool down to 60°C. 
4. Amounts of antibiotics (tetracycline and meropenem) were calculated according 
to 19 mL of MHA plate. Thus, antibiotic plates with different concentrations were 
prepared. 
5. One other set of antibiotic plates was prepared with addition of the pump inhibitor 
CCCP.  
6. 2 µL of diluted culture was spotted on every plate.  
7. Plates were incubated at 37°C for 18-24 hrs.  
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Day 3: 
     1. Results were analyzed to see the effect of the pump inhibitor on antimicrobial 
resistance. 
3.6: Effect of non-thermal plasma-treated methionine solution on the Minimum 
Inhibitory Concentration of CRAB #22 by agar dilution method  
A pump inhibition assay was performed to see if plasma-treated methionine solution was 
able to reduce the MIC of the CRAB #22 isolate. Plates with different concentrations of 
meropenem were prepared with and without plasma-treated solution. Plasma-treated 
solutions of methionine (solution treated for 1 minute and 2 minutes and untreated 
solution) were exposed to diluted bacterial culture in a 1:1 ratio for 10 minutes, and then 
after holding for 15 minutes, 2 µL was spotted on meropenem-containing plates. All 
plates were incubated overnight at 37°C and the next day the plates were checked to 
determine if there was any decrease in MIC by comparing plasma-treated plates with 
control plates (ones in which culture was exposed to plasma-untreated solution and ones 
without plasma-treated solution, i.e., only meropenem). 
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CHAPTER 4:  RESULTS AND ANALYSIS 
4.1 Interpretation of results  
4.1.1 Plasma experiments: All plasma treatment experiments were carried out with an 
initial bacterial concentration of 1x105 CFU/mL and it was taken as (0 minutes untreated 
sample) surviving cells in order to calculate the relative inactivation. All experiments 
were run in duplicates and had positive and negative controls. Results were interpreted by 
calculating the mean log and graphed to see the reduction of mean log with plasma 
treatment time.  
4.1.2 Susceptibility testing: MIC is expressed as the lowest dilution or concentration that 
inhibits the growth of the microorganism. 
4.1.2.1 Minimum inhibitory concentration by broth dilution method: Lack of 
turbidity is considered as inhibition of the organism. 
4.1.2.2 Minimum inhibitory concentration by agar dilution method: The antibiotic 
concentration of the first plate that shows no growth or inhibition of the organism is 
considered as the MIC of that organism.  
4.2 Results  
4.2.1 Non-thermal plasma treatment of 5 mM methionine solution: Various 
experiments were carried out to reach the predetermined results for plasma treatment by 
our laboratory.   
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Earlier it was reported that there is a total inactivation of bacteria at 3 minutes of plasma 
treatment for 15 minutes of holding time. Thus, we tried to replicate these results. 
4.2.1.1 In the first set of experiments, we compared the plasma-treated vs non-treated 
methionine solution for 5, 10, and 15 minutes of holding time (Figure 3) by taking only 
one strain, A. baumannii ATCC 19606. 
Holding time means we exposed non-treated or treated methionine solution to bacterial 
culture for a specific time.  
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Figure 3. Comparison of plasma-treated vs non-treated methionine solution for (A) 5, (B) 
10, and (C) 15 minutes of holding time and its effect on inactivation of the organism 
(ATCC 19606) 
(X-axis represents plasma treatment time and y-axis represents the mean log (CFU/ml) 
values) 
 
None of the holding times used resulted in complete inactivation; therefore, these results 
did not confirm the previously reported results, especially using a 15-minute holding 
time, which has been previously reported to inactivate the microorganism completely.  
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Then another set of experiments was carried out with different bacterial dilutions (Figure 
4 and Figure 5) and different ODs to see the effect of initial concentration of bacteria and 
OD on the size of log reduction (inactivation of organisms).  
 
Figure 4. Different dilutions of bacteria with an OD of 0.2 
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Figure 5. Different dilutions of bacteria with an OD of 0.115 
  
None of the different dilutions used with the two ODs resulted in complete inactivation. 
Thus, these results were also not in accordance with previously reported results. As a part 
of the troubleshooting process, we thought that maybe the thickness of the glass slide 
could be the reason for failure of the experiments, and thus we decided to change the 
glass fluid holder with a thinner glass slide, and another set of experiments was carried 
out (Figure 6).  
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Figure 6. Non-thermal plasma-activated methionine solution results in complete 
inactivation of organism (ATCC 19606) at 3 minutes of plasma treatment 
(X-axis represents plasma treatment time and y-axis represents the mean log (CFU/ml) 
values) 
 
 
Using a fluid holder made of thinner glass plate, we found that non-thermal plasma-
activated methionine solution resulted in complete inactivation of ATCC 19606 at 3 
minutes of plasma treatment after 15 minutes of holding time. These results confirmed 
the previously reported results of complete inactivation of organism. In order to 
reconfirm these results, we carried out plasma treatment of methionine at 1, 2, and 3 
minutes of plasma treatment for the two isolates (ATCC 19606 and CRAB #22).  
We found that non-thermal plasma-activated methionine solution was able to inactivate 
both isolates at 3 minutes of plasma treatment (Figure 7 and Figure 8).  
In Figure 7, it can be seen that, with increment in plasma treatment time, there is a 
decrease in mean log, which reached 0 indicating total inactivation at 3 minutes of 
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plasma treatment. The control here shows 70% ethyl alcohol was able to kill all the 
organisms.  Data demonstrates nearly a 5 log reduction at 3 minutes while 1- and 2-
minute plasma treatment do not have significant inactivation of bacterial cells.  
Figure 8 shows a similar result for ATCC 19606 susceptible isolate of A. baumannii: the 
total inactivation and 5 log reduction in CFU at 3 minutes of plasma treatment. 
 
 
Figure 7. Non-thermal plasma-activated methionine solution results in total inactivation 
of the CRAB #22 isolate at 3 minute of plasma treatment 
(X-axis represents plasma treatment time and y-axis represents the mean log (CFU/ml) 
values) 
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Figure 8. Non-thermal plasma-activated methionine solution results in total inactivation 
of ATCC 19606 susceptible isolate of A. baumannii at 3 minutes of plasma treatment 
 
4.2.2 Antibiotic susceptibility testing: MIC was determined for the antibiotics 
meropenem, tetracycline, and amikacin for the CRAB #22 isolate from our laboratory by 
the microbroth dilution method in 96-well plates (Tables 1 to 4). The highlighted 
concentration in each table is found to be the MIC of that particular antibiotic.  
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Table 1. MIC results by the microbroth dilution method for tetracycline (performed 
in duplicates)  
 
 
 
 
  1 2 
A 
#22 
Tetracycline 
 
Antibiotic 
concentration 
64 μg/mL 
 
64 μg/mL 
 
 
Corrected OD from 
Blank 
-0.006 -0.007 
B 
#22 
Tetracycline 
 
 
Antibiotic 
concentration 
32 μg/mL 
 
 
32 μg/mL 
 
Corrected OD from 
Blank 
-0.002 -0.004 
C 
#22 
Tetracycline 
 
Antibiotic 
concentration 
16 μg/mL 
 
 
16 μg/mL 
  
Corrected OD from 
Blank 
0.005 0.001 
D 
#22 
Tetracycline 
 
Antibiotic 
concentration 
8 μg/mL 
 
 
8 μg/mL 
  
 
Corrected OD from 
Blank 
0.065 0.011 
E 
#22 
Tetracycline 
 
Antibiotic 
concentration 
4 μg/mL 
 
4 μg/mL 
 
Corrected OD from 
Blank 
0.111 0.071 
F 
#22 
Tetracycline 
 
Antibiotic 
concentration 
2 μg/mL 
 
2 μg/mL 
 
Corrected OD from 
Blank 
0.178 0.122 
G 
#22 
Tetracycline 
 
Antibiotic 
concentration 
+ Control 
 
Neg 
 
Corrected OD from 
Blank 
0.214 0 
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Table 2. MIC results by the microbroth dilution method for meropenem   
 
  1 2 
A 
#22 
Meropenem 
 
Antibiotic 
concentration 
256 μg/mL 
 
256 μg/mL 
 
Corrected OD from 
Blank 
-0.005 -0.007 
B 
#22 
Meropenem 
 
Antibiotic 
concentration 
128 μg/mL 
 
128 μg/mL 
 
Corrected OD from 
Blank 
-0.006 -0.006 
C 
#22 
Meropenem 
 
Antibiotic 
concentration 
64 μg/mL 
 
64 μg/mL 
 
Corrected OD from 
Blank 
-0.006 -0.006 
D 
#22 
Meropenem 
 
 
Antibiotic 
concentration 
32 μg/mL 
 
32 μg/mL 
 
Corrected OD from 
Blank 
-0.006 -0.005 
E 
#22 
Meropenem 
 
Antibiotic 
concentration 
16 μg/mL 
 
16 μg/mL 
 
Corrected OD from 
Blank 
0.074 0.085 
F 
#22 
Meropenem 
 
Antibiotic 
concentration 
8 μg/mL 
 
8 μg/mL 
 
Corrected OD from 
Blank 
0.165 0.085 
G 
#22 
Meropenem 
 
Antibiotic 
concentration 
4 μg/mL 
 
4 μg/mL 
 
Corrected OD from 
Blank 
0.217 0.296 
H 
#22 
Meropenem 
 
Antibiotic 
concentration 
2 μg/mL 
 
2 μg/mL 
 
Corrected OD from 
Blank 
0.242 0.346 
I 
#22 
Meropenem 
 
Antibiotic 
concentration 
+ Control 
 
Neg 
 
Corrected OD from 
Blank 
0.327 0 
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Table 3. MIC results by the microbroth dilution method for amikacin 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  1 2 
A 
#22 
Amikacin 
Antibiotic 
concentration 
256 μg/mL 
 
256 μg/mL 
 
Corrected OD from 
Blank 
-0.004 -0.005 
B 
#22 
Amikacin 
Antibiotic 
concentration 
128 μg/mL 
 
128 μg/mL 
 
Corrected OD from 
Blank 
-0.003 -0.003 
C 
#22 
Amikacin 
 
Antibiotic 
concentration 
64 μg/mL 
 
64 μg/mL 
 
Corrected OD from 
Blank 
-0.003 -0.002 
D 
#22 
Amikacin 
 
 
Antibiotic 
concentration 
32 μg/mL 
 
32 μg/mL 
 
Corrected OD from 
Blank 
0.035 0.022 
E 
#22 
Amikacin 
 
Antibiotic 
concentration 
16 μg/mL 
 
16 μg/mL 
 
Corrected OD from 
Blank 
0.081 0.077 
F 
#22 
Amikacin 
 
Antibiotic 
concentration 
8 μg/mL 
 
8 μg/mL 
 
Corrected OD from 
Blank 
0.201 0.174 
G 
#22 
Amikacin 
 
Antibiotic 
concentration 
4 μg/mL 
 
4 μg/mL 
 
Corrected OD from 
Blank 
0.275 0.244 
H 
#22 
Amikacin 
 
Antibiotic 
concentration 
2 μg/mL 
 
2 μg/mL 
 
Corrected OD from 
Blank 
0.320 0.290 
I 
#22 
Amikacin 
 
Antibiotic 
concentration 
+ Control 
 
Neg 
 
Corrected OD from 
Blank 
0.249 0 
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Table 4. Overall MIC results by microbroth dilution method for three antibiotics  
 
Antibiotic     MIC (#22 Isolate) 
 
Tetracycline 
 
     16 µg/mL 
Meropenem 
 
      32 µg/mL 
Amikacin 
 
       64 µg/mL 
 
4.2.3 Determine the effect of efflux pump inhibitor on the antibiotic susceptibility of 
CRAB #22 isolate: In order to determine the role of efflux pump inhibitor in the 
antibiotic susceptibility phenotype of A. baumannii isolates, we measured the MICs of all 
three antibiotics in the presence and absence of the pump inhibitor CCCP. The pump 
inhibition assay was carried out with all three antibiotics and the pump inhibitor CCCP at 
a concentration of 12.5 µM. 
4.2.3.1 Minimum inhibitory concentration determination of meropenem and 
tetracycline with and without carbonyl cyanide m-chlorophenyl hydrazone by agar 
dilution method: According to the results obtained, there was no change in MIC for 
tetracycline, but there was a 2-fold reduction in MIC with meropenem (Table 5). 
 
 
 
 
 
 
33 
 
 
 
Table 5. MIC and fold reduction of meropenem and tetracycline with CCCP  
 
Antibiotic  
(Agar Dilution Method)  
MIC (µg/ml)     Fold Reduction 
in MIC  
Meropenem  
 
       32               
Meropenem + CCCP  
 
       16            2  
Tetracycline  
 
       16  
Tetracycline +CCCP 
 
       16             0 
 
4.2.3.2. Effect of carbonyl cyanide m-chlorophenyl hydrazone on amikacin by broth 
dilution method: The broth dilution method was carried out to see the effect of CCCP on 
amikacin (Table 6). There was no synergy found. Thus, CCCP did not have an effect on 
amikacin.  
Table 6. Effect of CCCP on amikacin by broth dilution method  
 
Antibiotic  
 
Synergy Fold reduction 
Amikacin + CCCP 
 
None None 
 
 
4.2.4 Effect of plasma-treated methionine solution on the minimum inhibitory 
concentration of CRAB #22 by agar dilution method: A pump inhibition assay was 
performed to see if plasma-treated methionine solution was able to reduce the MIC of the 
CRAB #22 isolate, but no synergy was found. 
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CHAPTER 5: CONCLUSION 
 
1. This study confirmed that plasma-treated methionine solution, at 3 minutes of 
plasma treatment and 15 minutes of holding time, results in complete inactivation 
of the organism. 
Thus, we were able to confirm the previous findings of the antimicrobial effect of 
non-thermal plasma-activated antibacterial solution. 
2. The studies investigated the effect of the commonly used pump inhibitor CCCP 
on meropenem, amikacin, and tetracycline susceptibility of CRAB #22 isolate. It 
is one of the widely used pump inhibitor for phenotypic pump inhibition assays 
(3). Therefore, in order to prevent the efflux of antibiotics and to regain the 
susceptibility of organism, we investigated its effect on the given isolate, whether 
it synergizes in restoring the susceptibility of the organism so that we could 
correlate its findings with the antimicrobial effect of non-thermal plasma with the 
inhibition of efflux pumps. But, in our study, CCCP did not decrease the MIC of 
amikacin and tetracycline, and therefore the functional efflux pump is not likely 
to be involved in resistance against the tested antimicrobials in this isolate. The 
CCCP did not have a significant effect on meropenem susceptibility as well; there 
is only a 2-fold reduction in MIC with meropenem. For the effect of CCCP to be 
considered significant, there should be a 4-fold or higher reduction in MIC. As 
many of the efflux pumps share the same structural homology, there might be 
other efflux pumps that are able to affect the susceptibility of the given isolate.  
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3. The agar dilution method could not determine the MIC of non-thermal plasma-
activated methionine solution, and the CCCP pump inhibition assay did not 
restore meropenem susceptibility. In order to investigate the effect of plasma-
treated antibacterial solution on inhibition of drug-efflux pumps, other efflux 
pump inhibitors may be tested for the given isolate that may have significant 
effects in inhibition of efflux pumps.  
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CHAPTER 6: DISCUSSION 
 
Acinetobacter baumannii is one of the most important nosocomial pathogens commonly 
found in critical care units and  healthcare centers worldwide (4). Carbapenems are the 
antimicrobial agents found to be the last resort to treat infections caused by MDR 
organisms such as  A. baumannii, but due to increased carbapenem resistance among 
these pathogenic organisms treatment options in the clinical setting have become a 
concern (18). 
One of the major mechanisms in the carbapenem resistance in A. baumannii is the 
involvement of active efflux pumps (4). There are other mechanisms of carbapenem 
resistance in A. baummnnii that are prevalent. Molecular epidemiological analysis and 
periodic surveillance at regional healthcare centers are therefore important in making 
therapeutic decisions. Overexpression of these pumps is found to be responsible for the 
MDR in this organism. For example, two RND efflux systems AdeABC and AdeIJK 
have been found to be involved in the MDR of A. baumannii. The adeABC operon has 
been found in almost 80% of the clinical isolates. Overexpression of the AdeABC system 
is regulated by the two component system AdeRS. It has been found that point mutations 
in AdeR-AdeS results in overexpression of AdeABC system or insertion of ISAba1 can 
also results in its overexpression (37). 
The efflux system generally comprises transport proteins that extrude toxic compounds 
from the cytoplasmic membrane including antibiotics. In this way, the intracellular 
concentration of antibiotic is decreased; hence, it results in less susceptibility of the 
bacterial organism to the antimicrobial agent (38). The MIC of the antibiotic for the 
strains in which there is overexpression of the efflux pumps usually are 2- to 8-fold 
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higher than the susceptible strains (38). We carried out MIC susceptibility testing for the 
CRAB isolate #22 and reference strain ATCC 19606 for meropenem. And we found the 
MIC of the resistant strain #22 was 8-fold higher than the MIC of the susceptible strain 
ATCC 19606. 
The cell envelope of bacteria contains protein channels that can transport various 
molecules such as sugars and amino acids, but also toxic compounds such as antibiotics 
and biocides. Energy-dependent active efflux pumps are one of these transporters that 
recognize these toxic molecules such as antibiotics and transport them away from the 
cytoplasmic membrane. Overexpression of these pumps confers resistance to organisms. 
Sometimes overproduction of these pump systems is associated with increased resistance 
to unrelated antimicrobial agents too that results in the emergence of MDR pathogens (3). 
So, in order to control these pathogens, it is important to prevent the efflux, and this is 
possible by developing new compounds or approaches or strategies that can change the 
susceptibility of antibiotics by inhibiting drug efflux. These pathogens can be controlled 
even by developing such molecules that can decrease the effectiveness of the outer 
membrane barrier so that it will not reject antimicrobial agents and thus would result in 
increased intracellular concentrations of antibiotic and increased influx (3).  
Efflux pump inhibitors are known to be effective therapeutic agents. It has been found 
that the combination of efflux pump inhibitor and antibiotic is likely to increase the 
intracellular concentration of antibiotic, which reverses the resistance obtained by the 
overexpression of efflux pumps and thus results in reducing the rise of resistant mutant 
strains (39). 
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There are many commercially available pump inhibitors that can inhibit the drug-efflux 
pumps. The CCCP is one of the widely used pump inhibitor for phenotypic pump 
inhibition assays. CCCP is known to disrupt the proton gradient of the membrane, which 
results in the increase of susceptibility of the organism (3). 
Efflux pump inhibitors can obstruct the efflux system by blocking the energy source of 
the pump and making bacterial cells susceptible to the antimicrobial agents. There are 
various pump inhibitors that have been reported in A. baumannii including CCCP, 
phenylalanine-arginine β-naphthylamide, reserpine, and verapamil. These inhibitors do 
not have any effect on the bacterial cells unless they are used synergistically (in 
combination with) antibiotics. It has been reported that the efflux pump inhibitor 1-(1-
naphthyl-methyl)-piperazine can moderately reverse the MDR in A. baumannii (40).  
But, in our current study, we were unable to see a significant effect of CCCP on the 
CRAB isolate. As many inhibitors share structural homology, there might be other efflux 
pump inhibitors that are able to affect the susceptibility of a given isolate.  
Till now, no efflux pump inhibitors are licensed for use in the human clinical setting 
because the effective inhibitory concentration is far greater than the concentration being 
used in clinical setting and thus it can be toxic to patients. Therefore, this area needs 
further research so that new efflux pump inhibitors can be developed to control the 
mortality rate of infections associated with MDR pathogens (3).  
Recently, non-thermal plasma has become of high significance due to its antimicrobial 
effect (1). For many years, non-thermal plasma has been used in many applications 
including removal of the gaseous pollutants and low-temperature plasma chemistry, but 
during the past few years non-thermal plasma has emerged as highly significant because 
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of its antimicrobial activity. Therefore, the use of non-thermal plasma has been increased 
and expanded to many biological applications such as inhibition of biofilm, inactivation 
of microorganisms, and preparation of ready-to-eat foods and also to the healthcare 
setting such as treatment of infected wounds and control of nosocomial infections (41). 
The Drexel Plasma Institute and our laboratory for the first time used a concept of 
floating electrode DBD probe for the treatment of biomaterials and solutions/liquids. It 
has been found that liquids treated by plasma produce variable amounts of reactive 
species and different kinds of reactive species (depending upon the solution or liquid 
being treated). Reactive oxygen species are known to be bactericidal but can have 
damaging effects on the host as well. The damage to the bacterial cell is mediated by loss 
of membrane potential, lipid peroxidation, protein oxidation, inactivation of functional 
groups of proteins, and DNA damage, leading to loss of the integrity of the bacterial cell 
membrane and severe oxidative stress that leads to cell death. Thus, liquids treated by 
plasma acquire strong antimicrobial activity and are generally broad-spectrum in nature 
(42).  
In previous findings from the Joshi Laboratory, it was demonstrated that plasma-activated 
methionine solution can inhibit the biofilm formation by MDR pathogens such as CRAB, 
methicillin-resistant Staphylococcus aureus, Enterococcus faecalis, and metallo-β-
lactamase-positive Klebsiella pneumonia (2). According to one study from our 
laboratory, the major chemical species involved in effective microbial inactivation have 
been revealed. They found that plasma-activated NAC solution creates reactive oxygen 
and reactive nitrogen species and peroxynitrite, which is responsible for the effective 
inactivation of bacterial organisms (1). 
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In the present study, we confirmed the finding that non-thermal plasma-activated 
methionine solution leads to complete inactivation of the CRAB isolate #22, but the exact 
underlying mechanisms and the exact chemistry of this solution need to be studied.   
In order to further investigate the effects on pump inhibition, we should explore the 
chemistry contributing to inactivation of this organism. There is scope for testing 
additional efflux pump inhibitors (with or without antimicrobial agents or plasma-
activated methionine) to demonstrate whether any other inhibitor synergizes in restoring 
carbapenem susceptibility in CRAB #22. These findings can then help to correlate the 
antimicrobial effect of non-thermal plasma with the inhibition of efflux pumps. 
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